Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

G-CSF Plus Preemptive Plerixafor Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma: Effectiveness, Safety and Cost Analysis

Ahmad Antar, MD, Zaher Otrock, MD, Mohamed Kharfan-Dabaja, MD, Hussein Abou Ghaddara, MD, Nabila Kreidieh, CLS, Rami Mahfouz, MD MPH, Ali Bazarbachi, MD PhD

Blood (2014) 124 (21): 5823.

https://doi.org/10.1182/blood.V124.21.5823.5823

Published: 2014

Journal Articles

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Chiara Frairia, MD, Jamie Shapiro, PharmD, Jongphil Kim, PhD, Joseph Pidala, MD PhD, Ernesto Ayala, MD, Brian C Betts, MD, Hugo F Fernandez, MD, Teresa Field, MD PhD, Mohamed Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Marcie L Riches, MD MS, Claudio Anasetti, MD

Blood (2014) 124 (21): 2500.

https://doi.org/10.1182/blood.V124.21.2500.2500

Published: 2014

Journal Articles

Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL

Marays Veliz, M.D., John Powers, Ling Zhang, MD, Enrique Santana, RN, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Mohamed Kharfan-Dabaja, MD, Sara Tinsley, ARNP, Darcie Deaver, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD

Blood (2010) 116 (21): 4630.

https://doi.org/10.1182/blood.V116.21.4630.4630

Published: 2010

Journal Articles

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Janelle Perkins, PharmD, Teresa Field, MD, PhD, Jongphil Kim, PhD, Hugo F. Fernandez, MD, Lia Perez, MD, Ernesto Ayala, MD, Mohamed Kharfan-Dabaja, MD, Marcie Tomblyn, MD, MS, Daniel Sullivan, MD, Claudio Anasetti, MD

Blood (2010) 116 (21): 3499.

https://doi.org/10.1182/blood.V116.21.3499.3499

Published: 2010

Journal Articles

Antithymocyte Globulin (ATG) for Graft-Versus-Host-Disease (GvHD) Prophylaxis In Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT): a Systematic Review and Meta-Analysis.

Ambuj Kumar, MD, MPH, Asmita R Mhaskar, MPH, Mohamed Kharfan-Dabaja, MD, Claudio Anasetti, MD, Mohamad Mohty, Benjamin Djulbegovic, MD, PhD

Blood (2010) 116 (21): 1513.

https://doi.org/10.1182/blood.V116.21.1513.1513

Published: 2010

Journal Articles

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Jongphil Kim, Ernesto Ayala, MD, Melissa Alsina, MD, Jose-Leonel ochoa-Bayona, M.D., Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 1333.

https://doi.org/10.1182/blood.V116.21.1333.1333

Published: 2010

Journal Articles

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Jose-Leonel ochoa-Bayona, M.D., Melissa Alsina, MD, Ernesto Ayala, MD, Jongphil Kim, Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 2381.

https://doi.org/10.1182/blood.V116.21.2381.2381

Published: 2010

Journal Articles

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Todd Alekshun, MD, Christine Mcisaac-Simonelli, RN, Mohamed Kharfan-Dabaja, MD, William Dalton, MD, PhD, Benjamin Djulbegovic, MD, Hugo Fernandez, MD, Daniel M. Sullivan, MD, Ernesto Ayala, MD, Teresa L. Field, MD, Dawn Garrett, LPN, William E. Janssen, PhD, Beth Maddox, RN, Lia Perez, MD, Dawn Kettner, PA, Janelle Perkins, PharmD, Jyoti Raychaudhuri, MD, Claudio Anasetii, MD, Melissa Alsina, MD

Blood (2007) 110 (11): 5131.

https://doi.org/10.1182/blood.V110.11.5131.5131

Published: 2007

Journal Articles

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Daniel Sullivan, MD, Melissa Alsina, MD, Claudio Anasetti, MD, Teresa Field, MD, PhD, Mohamed Kharfan-Dabaja, MD, Hugo Fernandez, MD, William Dalton, PhD, MD, Ernesto Ayala, MD, Jyoti Raychaudhuri, MD, Lia Perez, MD, Janelle Perkins, PharmD, Michael Schell, PhD, Christine McIsaac, RN, Beth Maddox, RN, Jana Gump, BS, Richard Lush, PhD, Tony Frudakis, PhD

Blood (2007) 110 (11): 943.

https://doi.org/10.1182/blood.V110.11.943.943

Published: 2007

Journal Articles

Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodysplastic Syndrome (MDS).

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Melissa Alsina, MD, Ernesto Ayala, MD, Hugo F. Fernandez, MD, William Janssen, PhD, Mohamed Kharfan-Dabaja, MD, Jeffery Lancet, MD, Lia Perez, MD, Daniel Sullivan, MD, Alan List, MD, Claudio Anasetti, MD

Blood (2006) 108 (11): 3664.

https://doi.org/10.1182/blood.V108.11.3664.3664

Published: 2006

Journal Articles

Busulfan Area-under-the-Curve Finding Study within a Busulfan/Fludarabine (BuFlu) Conditioning Regimen before Allogeneic Hematopoietic Cell Transplantation (HCT).

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Melissa Alsina, MD, Ernesto Ayala, MD, Karen Fancher, PharmD, Hugo F. Fernandez, MD, Dawn Garrett, LPN, William Janssen, PhD, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Daniel Sullivan, MD, Cheryl Tate, PharmD, Claudio Anasetti, MD

Blood (2006) 108 (11): 2939.

https://doi.org/10.1182/blood.V108.11.2939.2939

Published: 2006

NARROW

G-CSF Plus Preemptive Plerixafor Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma: Effectiveness, Safety and Cost Analysis

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Antithymocyte Globulin (ATG) for Graft-Versus-Host-Disease (GvHD) Prophylaxis In Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT): a Systematic Review and Meta-Analysis.

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodysplastic Syndrome (MDS).

Busulfan Area-under-the-Curve Finding Study within a Busulfan/Fludarabine (BuFlu) Conditioning Regimen before Allogeneic Hematopoietic Cell Transplantation (HCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only